ICU · GI/Nutrition
Acute-on-chronic liver failure (ACLF)
Also known as Acute-on-chronic liver failure (ACLF) · CLIF-C score · APASL ACLF · Liver transplant for ACLF · CANONIC criteria · CLIF-C OF score · Cirrhosis with organ failure
ACLF is acute decompensation of known cirrhosis with organ failure(s), exaggerated systemic inflammation, and high 28-day mortality — distinct from simple decompensation. Precipitants: bacterial infection first (none identified in about 40 percent), alcohol-associated hepatitis, GI bleed, drugs, viral hepatitis. CLIF-C OF grades six organ domains; CLIF-C ACLF adds age and white count and is recalculated at 48 hours. Without transplant, 28-day mortality runs about 18 to 25 percent in grade 1 and 68 to 89 percent in grade 3; transplant in selected grade 2 to 3 patients raises 6-month survival from about 10 to about 80 percent. Treatment: manage the precipitant, organ support, terlipressin plus albumin for HRS-AKI (CONFIRM), albumin 1.5 g per kg then 1 g per kg for SBP (Sort), prednisolone only for severe alcohol-associated hepatitis with day-7 Lille reassessment, no INR correction before procedures, no protein restriction.
Checked against its sources on 8 Oct 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- ACLF grade 3 (3 or more organ failures) carries 68 to 89 percent 28-day mortality without transplant — early transplant referral
- Infection is the number-one precipitant — search aggressively (cultures, ascitic tap)
- Do NOT give steroids for ACLF itself — first-line only in severe alcohol-associated hepatitis (more infections, no proven ACLF benefit)
- Liver transplant is the best treatment — in selected grade 2 to 3 patients it raises 6-month survival from about 10 to about 80 percent
- HRS-AKI is reversible with terlipressin plus albumin — diagnose and treat early, and watch for fluid-overload respiratory failure (CONFIRM)
- INR reflects liver synthetic function, NOT bleeding risk — do NOT routinely correct with FFP
- Cirrhosis has REBALANCED haemostasis — use viscoelastic testing (TEG/ROTEM), not INR
Meet the patient
A 58-year-old man with alcohol-related cirrhosis, known varices on nadolol, is admitted with 36 hours of fever, abdominal pain, and worsening confusion — intubated for a GCS of 8, on noradrenaline for MAP 65, with tense ascites, asterixis, and an ascitic tap showing 740 polymorphs per mm cubed.[1]
The question that frames his stay is the question that frames every ACLF: how many organs have failed? Grade the CLIF-C OF score, name the precipitant (here spontaneous bacterial peritonitis), and the mortality, the terlipressin decision, and the transplant clock all fall into place.[3]
References30ShowHide
- [1]EASL Clinical Practice Guidelines. EASL Clinical Practice Guidelines on acute-on-chronic liver failure J Hepatol, 2023.PMID 37364789
- [2]Sarin SK, Choudhury AK, Sharma MK, et al. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia Hepatol Int, 2025.PMID 39961976
- [3]Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis Gastroenterology, 2013.PMID 23474284
- [4]Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure J Hepatol, 2014.PMID 24950482
- [5]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
- [6]Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure Gastroenterology, 2009.PMID 19524577
- [7]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
- [8]Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial Lancet, 2018.PMID 29861076
- [9]Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis N Engl J Med, 2015.PMID 25901427
- [10]Cavallin M, Piano S, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016.PMID 26659927
- [11]Saif RU, Dar HA, et al. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol, 2018.PMID 30178092
- [12]Sharma P, Kumar A, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol, 2008.PMID 18557715
- [13]Wan YM, Huang SQ, et al. Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Front Pharmacol, 2024.PMID 39295934
- [14]Jalan R, Gustot T, et al. 'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action. J Hepatol, 2021.PMID 34171434
- [15]Arroyo V, Moreau R, et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers, 2016.PMID 27277335
- [16]Nadim MK, Kellum JA, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol, 2024.PMID 38527522
- [17]Angeli P, Garcia-Tsao G, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019.PMID 31302175
- [18]Angeli P, Labenz C, et al. Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus. J Hepatol, 2025.PMID 40250764
- [19]Bass NM, Mullen KD, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med, 2010.PMID 20335583
- [20]Lee TH, et al. [Nutritional Assessment and Management for Patients with Chronic Liver Disease]. Korean J Gastroenterol, 2018.PMID 29684966
- [21]Özden Y, Sağlam O Development and internal validation of the SCAN score: a pragmatic bedside tool for early prediction of spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Clin Exp Hepatol, 2026.PMID 42221311
- [22]Mathurin P, Louvet A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA, 2013.PMID 24026598
- [23]Sidhu SS, Goyal O, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci, 2012.PMID 22388710
- [24]Wang ML, Yin XJ, et al. Retrospective Analysis of the Clinical Efficacy of N-Acetylcysteine in the Treatment of Hepatitis B Virus Related Acute-on-Chronic Liver Failure. Front Med, 2021.PMID 34422872
- [25]Bull-Henry K, et al. Endoscopy in the coagulopathic patient. Curr Opin Gastroenterol, 2019.PMID 31343417
- [26]Kujovich JL, et al. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program, 2015.PMID 26637729
- [27]Bernal W, Jalan R, et al. Acute-on-chronic liver failure. Lancet, 2015.PMID 26423181
- [28]Ballester MP, Sittner R, et al. Alcohol and Acute-on-Chronic Liver Failure. J Clin Exp Hepatol, 2022.PMID 36157143
- [29]Br VK, Sarin SK Acute-on-chronic liver failure: Terminology, mechanisms and management. Clinical and molecular hepatology, 2023.PMID 36938601
- [30]Rashed E, Soldera J CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review. World journal of hepatology, 2022.PMID 36618331